# BIG 02/98 Docetaxel - Breast Cancer

> **NCT00174655** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 2887 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Doxorubicine + docetaxel sequential
- **DRUG:** doxorubicine + cyclophosphamide sequential
- **DRUG:** doxorubicine + cyclophosphamide combined
- **DRUG:** doxorubicine + docetaxel combined

## Key facts

- **NCT ID:** NCT00174655
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-06
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 2887 (ACTUAL)
- **Last updated:** 2011-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00174655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00174655, "BIG 02/98 Docetaxel - Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00174655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*